- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Ambry Genetics Shares New Data on Genetic Causes for Neurodevelopmental Conditions
Ambry Genetics announced data identifying potential new genetic links to neurodevelopmental conditions.
Ambry GeneticsĀ announced data identifying potential new genetic links to neurodevelopmental conditions.
According to the news:
The findings, shared today in oral platform presentations at the American College of Medical Genetics and Genomics (ACMG) 2016 Annual Clinical Genetics Meeting in Tampa, FL, were based on genetic testing results conducted by Ambry, including diagnostic exome sequencing (DES).
Aaron Elliott, Ph.D., Chief Operating Officer and Interim Chief Scientific Officer, Ambry Genetics commented:
Neurodevelopmental disorders represent a challenging diagnosis because the underlying cause is not always readily understood. With exome sequencing and other genetic tests, we are starting to uncover disease-causing gene mutations in neurology that may have important clinical implications.Ā The findings presented today in these oral presentations further add to our growing body of data that we hope will offer healthcare providers and their patients with some of the answers they are seeking.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to theĀ cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Ā